SCHEMBL933765

SCHEMBL933765

COc1ccc(SC(C(=O)O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.51
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HPGD P15428 1/20 0.49
ADAM17 P78536 1/20 0.47
CNR2 P34972 1/20 0.47
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HTT P42858 1/20 0.43
MEN1 O00255 1/20 0.43
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
UTS2R Q9UKP6 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11761904 1.00 TRPA1 (0.51) TRPA1CYP2C9CYP2C19HSD17B10HPGD
SCHEMBL3521016 0.87 CYP2C9 (0.63) TRPA1CYP2C9CYP2C19HSD17B10KMT2A
SCHEMBL6785712 0.87 ADAM17 (0.48) ADAM17KMT2AALDH1A1LMNAMAPT
SCHEMBL6934273 0.86 MAPT (0.55) ADAM17KMT2AALDH1A1LMNAMAPT
SCHEMBL11293629 0.86 MAPT (0.55) ADAM17CNR2KMT2AALDH1A1LMNA
SCHEMBL11565222 0.84 PPARA (0.49) CYP2C9CYP2C19HSD17B10KMT2AMEN1
SCHEMBL28465400 0.83 TRPA1 (0.47) TRPA1CYP2C9CYP2C19HSD17B10HPGD
SCHEMBL933757 0.83 CYP2C9 (0.54) TRPA1CYP2C9CYP2C19HSD17B10CNR2
SCHEMBL11471615 0.82 MAPT (0.45) ADAM17KMT2AALDH1A1LMNAMAPT
SCHEMBL11564065 0.82 PPARA (0.47) CYP2C9CYP2C19HSD17B10ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS ALLERGAN, INC. (US) 2012-04-12 US disclosed
WO-2011008475-A1 OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES ALLERGAN, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS S1PR3, S1PR5, S1PR1 TRPA1 315/4885CYP2C9 2965/4885CYP2C19 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.